The inhibitory avoidance test optimized for discovery of cognitive enhancers

Detrait, Eric; Hanon, Étienne; Dardenne, B.; Lamberty, Yves

doi:10.3758/brm.41.3.805

Cited by 19 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also altered the protocol for the passive avoidance test by adding a second training trial 2 min after the first one. We made this change to ensure sufficient training for Fmr1 KO mice [16]. This change in protocol also gave us an indication of short-term memory function in Fmr1 KO mice.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome

Qin

Zeidler

Moulton

et al. 2015

Behavioural Brain Research

View full text Add to dashboard Cite

Silencing the gene FMR1 in fragile X syndrome (FXS) with consequent loss of its protein product, FMRP, results in intellectual disability, hyperactivity, anxiety, seizure disorders, and autism-like behavior. In a mouse model (Fmr1 knockout (KO)) of FXS, a deficit in performance on the passive avoidance test of learning and memory is a robust phenotype. We report that drugs acting on the endocannabinoid (eCB) system can improve performance on this test. We present three lines of evidence: (1) Propofol (reported to inhibit fatty acid amide hydrolase (FAAH) activity) administered 30 min after training on the passive avoidance test improved performance in Fmr1 KO mice but had no effect on wild type (WT). FAAH catalyzes the metabolism of the eCB, anandamide, so its inhibition should result in increased anandamide levels. (2) The effect of propofol was blocked by prior administration of the cannabinoid receptor 1 antagonist AM-251. (3) Treatment with the FAAH inhibitor, URB-597, administered 30 min after training on the passive avoidance test also improved performance in Fmr1 KO mice but had no effect on WT. Our results indicate that the eCB system is involved in FXS and suggest that the eCB system is a promising target for treatment of FXS.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Mice did not receive a shock during the testing. The maximum time allowed was 300 s. A second protocol designed to enhance learning was instituted for all other studies [16]. This protocol was the same as the first with the introduction of a second training trial on Day 2, 120 s after the first trial.…”

Section: Methodsmentioning

confidence: 99%

Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome

Qin

Zeidler

Moulton

et al. 2015

Behavioural Brain Research

View full text Add to dashboard Cite

show abstract

“…Studies of the HA effects on inhibitory avoidance were performed by Almeida and Izquierdo (1986) and extensively described over recent years (Benetti and Izquierdo, 2013;Bonini et al, 2011;Da Silva et al, 2006;Detrait et al, 2009). In the present investigation, IA behavior was studied in a two-trial learning, stepthrough situation (Fine et al, 1985;Page et al, 1991), which utilizes the natural preference of rodents for dark environments due to their photophobia (Detrait et al, 2009). A box (48 × 27 × 30 cm) composed of acrylic plates consisted of two compartments: a bright compartment (crystal colored, 456 lx luminosity, 24 × 13.5 × 15 cm) and a dark compartment (black colored, 24 × 13.5 × 15 cm), with a guillotine type door (7 × 7 cm) in the middle of the divider wall.…”

Section: Animalsmentioning

confidence: 99%

Impairment in the aversive memory of mice in the inhibitory avoidance task but not in the elevated plus maze through intra-amygdala injections of histamine

Daher

Mattioli

2015

Pharmacology Biochemistry and Behavior

View full text Add to dashboard Cite

show abstract

“…On the other hand, ST-IA training with a very high foot shock, considered as an over-reinforcement, protected from the amnestic effect of a high dose (4 mg/kg) of systemic scopolamine 25 . The steps down condition avoid response produced by the memory improvement.…”

Section: Fig 14: Scopolamine Induced Memory Deficits In Inhibitory Smentioning

confidence: 96%

Untitled

2018

IJPSR

View full text Add to dashboard Cite

The objective of this study was to formulate and characterize Tacrine loaded poly (lactide-co-glycolide) (PLGA) nanoparticles used for the treatment of alzheimer's disease and were prepared by modified nano precipitation method. Pharmacodynamics studies of the nanoparticles were evaluated for brain targeting and memory improvement in scopolamineinduced amnesic mice using Morris water maze test and inhibitory step down avoidance. The nanoparticles were characterized for drug content, particle size and particle morphology using TEM. In-vitro studies were determined by diffusion cells. The particle size of the prepared nanoparticles ranged from 247 nm to 293 nm. Nanoparticles of Tacrine were obtained with entrapment efficiency of 72.34-81.32%. The drug release from the Tacrine nanoparticles was sustained in batch TPGN-3for 24 h with 85.67% drug release. The in-vitro cytotoxicity studies indicate that the IC 50 of the Tacrine loaded nanoformulations shown improved in the reduction of the IC 50 but plain nanoparticles did not show severe cytotoxicity. In cellular uptake study of the optimized formulation TPGN-3, shows significant intracellular accumulation when compared with pure drug and control. Pharmacodynamics study indicates that faster regain of memory in amnesic mice with PLGA nanoparticles when compared to pure drug Tacrine. This study indicates that the higher extent of transport of Tacrine in mice brain and shows improved therapeutic efficacy of Tacrine in the treatment of alzheimer's disease.

show abstract

The inhibitory avoidance test optimized for discovery of cognitive enhancers

Cited by 19 publications

References 21 publications

Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome

Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome

Impairment in the aversive memory of mice in the inhibitory avoidance task but not in the elevated plus maze through intra-amygdala injections of histamine

Untitled

Contact Info

Product

Resources

About